More than one million bone grafting procedures are performed annually for debilitating pain and bone conditions, emphasizing the increasing need for efficient bone graft substitutes. Autografts are considered the “gold standard” as they provide the most successful treatment outcomes which far exceed any other products in the market. Unfortunately, the autograft harvesting procedure can lead to significant donor site morbidity including chronic pain and fracture. A safe replacement product that is as efficient as autografts can revolutionize the way we treat patients with severe bone conditions. Our bone product is currently developed as a replacement for autografts and is optimized for rapid bone repair and regeneration.